Which are the $2$ recent incentivized programs in which products were approved in $2018$ and $2019$ under these incentivized pathways?

Group of answer choices

Orphan drug designation $($ODD$)$

RMAT $($Regenerative medicine advanced therapy $($RMAT$)$

Rare Pediatric Disease $($RPD$)$

Tropical Diseases Priority Review Voucher $($PRV$)$ program

Limited Population Pathway for Antibacterial and Antifungal Drugs

A and B

B and D

All of the above